Brain Natriuretic Peptide Release in Cardiac Surgery Patients

Abstract

Brain natriuretic peptide (BNP) release is a marker of increased myocardial wall tension, which is elevated in patients with disturbed left ventricular function. As it is increasingly being used as a reliable marker for diagnosis, optimization of pharmacological treatment, and risk stratification, BNP measurement might be also relevant for patients undergoing cardiac surgery. Measured BNP levels can be used to predict postoperative complications and the risk of further cardiac events. Preoperative BNP levels support the decision for the timing of aortic valve replacement in asymptomatic severe aortic stenosis. An increase in BNP levels early predicts allograft rejection after cardiac transplantation or ineffective cardiac resynchronization therapy. Moreover, BNP levels can be used to differentiate between cardiac and non-cardiac reasons for acute dyspnea in the management of surgical patients. Finally, the application of recombinant human BNP seems to improve recovery after cardiac surgical procedures.

Thus, BNP can be a helpful tool for monitoring and treating patients before, during, and after cardiac surgery to predict and improve the effectiveness of therapy and reduce hospitalization and costs.

Key words

Brain natriuretic peptide - heart failure - cardiac surgery - heart transplantation - cardiac resynchronization therapy

References

• 1 Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain.  Nature. 1988;  332 78-81
• 2 Yasue H, Yoshimura M, Sumida H. et al . Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.  Circulation. 1994;  90 195-203
• 3 DeLemos J A, McGuire D K, Drazner M H. B-type natriuretic peptide in cardiovascular disease.  Lancet. 2003;  362 316-322
• 4 Levin E R, Gardner D G, Samson W K. Natriuretic peptides.  N Engl J Med. 1998;  339 321-328
• 5 Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction.  Am Heart J. 1998;  135 825-832
• 6 Cao L, Gardner D G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts.  Hypertension. 1995;  25 227-234
• 7 Tamura N, Ogawa Y, Chusho H. et al . Cardiac fibrosis in mice lacking brain natriuretic peptide.  PNAS. 2000;  97 4239-4244
• 8 Fischer Y, Filzmaier K, Stiegler H. et al . Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide.  Clin Chem. 2001;  47 591-594
• 9 Maisel A S, Koon J, Krishnaswamy P. et al . Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction.  Am Heart J. 2001;  141 367-374
• 10 McDonagh T A, Robb S D, Morton J J. et al . Biochemical detection of left-ventricular systolic dysfunction.  Lancet. 1998;  351 9-13
• 11 Wieczorek S J, Wu A H, Christenson R. et al . A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation.  Am Heart J. 2002;  144 834-839
• 12 Lubien E, DeMaria A, Krishnaswamy P. et al . Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings.  Circulation. 2002;  105 595-601
• 13 Troughton R W, Prior D L, Pereira J J. et al . Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function.  J Am Coll Cardiol. 2004;  43 416-422
• 14 Redfield M M, Rodeheffer R J, Jacobsen S J. et al . Plasma brain natriuretic peptide concentration: impact of age and gender.  J Am Coll Cardiol. 2002;  40 976-982
• 15 McCullough P A, Duc P, Omland T. et al . B -type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.  Am J Kidney Dis. 2003;  41 571-579
• 16 Wang T J, Larson M G, Levy D. et al . Impact of obesity on plasma natriuretic peptide levels.  Circulation. 2004;  109 594-600
• 17 McNairy M, Gardetto N, Clopton P. et al . Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide.  Am Heart J. 2002;  143 406-411
• 18 Pfister R, Scholz M, Wielckens K. et al . Use of NT-proBNP in routine testing and comparison to BNP.  Eur J Heart Fail. 2004;  6 289-294
• 19 Collinson P O, Barnes S C, Gaze D C. et al . Analytical performance of N terminal pro B type natriuretic peptide (NT-proBNP) assay on the ElecsysTM 1010 and 2010 analysers.  Eur J Heart Fail. 2004;  6 365-368
• 20 Berendes E, Schmidt C, van Aken H. et al . A-type and B-type natriuretic peptides in cardiac surgical procedures.  Anesth Analg. 2004;  98 11-19
• 21 Hutfless R, Kazanegra R, Madani M. et al . Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery.  J Am Coll Cardiol. 2004;  43 1873-1879
• 22 Wazni O M, Martin D O, Marrouche N F. et al . Plasma B-type natriuretic peptide levels predict postoperative atrial fibrillation in patients undergoing cardiac surgery.  Circulation. 2004;  110 124-127
• 23 Avidan M S, Meehan N, Ponte J, El-Gamel A, Sherwood R A. Changes in brain natriuretic peptide concentrations following open cardiac surgery with cardioplegic cardiac arrest.  Clin Chim Acta. 2001;  303 127-132
• 24 Chello M, Mastroroberto P, Perticone F. et al . Plasma levels of atrial and brain natriuretic peptides as indicators of recovery of left ventricular systolic function after coronary artery bypass.  Eur J Cardiothor Surg. 2001;  20 140-146
• 25 Watanabe M, Egi K, Hasegawa S. et al . Significance of serum atrial and brain natriuretic peptide release after coronary artery bypass grafting.  Surg Today. 2003;  33 671-673
• 26 Bergler-Klein J, Klaar U, Heger M. et al . Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis.  Circulation. 2004;  109 2302-2308
• 27 Eimer M J, Ekery D L, Rigolin V H. et al . Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function.  Am J Cardiol. 2004;  94 676-678
• 28 El Gamel A, Yonan N A, Keevil B. et al . Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation.  Ann Thorac Surg. 1997;  63 1095-1100
• 29 Chin C, Akhtar M J, Rosenthal D N, Bernstein D. Safety and utility of the routine surveillance biopsy in pediatric patients 2 years after heart transplantation.  J Pediatr. 2000;  136 238-242
• 30 Masters R G, Davies R A, Veinot J P, Hendry P J, Smith S J, de Bold A J. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans.  Circulation. 1999;  100 287-291
• 31 Claudius I, Lan Y T, Chang R K, Wetzel G T, Alejos J. Usefulness of B-type natriuretic peptide as a noninvasive screening tool for cardiac allograft pathology in pediatric heart transplant recipients.  Am J Cardiol. 2003;  92 1368-1370
• 32 Auricchio A, Stellbrink C, Block M. et al . The effect of pacing chamber and atrioventricular delay on acute systolic function of paced patients with congestive heart failure.  Circulation. 1999;  99 2993-3001
• 33 Breithardt O A, Sinha A M, Schwammenthal E. et al . Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure.  J Am Coll Cardiol. 2003;  41 765-770
• 34 Cazeau S, Leclercq C, Lavergne T. et al . Multisite stimulation in cardiomyopathies (MUSTIC) study investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.  N Engl J Med. 2001;  344 873-880
• 35 Abraham W T, Fisher W G, Smith A L. et al . Cardiac resynchronization in chronic heart failure.  N Engl J Med. 2002;  346 1845-1853
• 36 Auricchio A, Stellbrink C, Sack S. et al . Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay.  J Am Coll Cardiol. 2002;  39 2026-2033
• 37 Stellbrink C, Breithardt O A, Franke A. et al . Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbance.  J Am Coll Cardiol. 2001;  38 1957-1965
• 38 Sinha A M, Filzmaier K, Breithardt O A. et al . Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure.  Am J Cardiol. 2003;  91 755-758
• 39 Sinha A M, Filzmaier K, Kunz D. et al . Correlation of brain natriuretic peptide release, cardiopulmonary exercise testing and 6 minute walking test in patients with heart failure and cardiac resynchronization therapy.  J Am Coll Cardiol. 2003;  41 60 (abstract)
• 40 Maisel A S, Krishnaswamy P, Nowak R M. et al . Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.  N Engl J Med. 2002;  347 161-167
• 41 Maisel A S, McCord J, Nowak R M. et al . Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study.  J Am Coll Cardiol. 2003;  41 2010-2017
• 42 Morrison L K, Harrison A, Krishnaswamy P. et al . Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung diseases in patients presenting with dyspnea.  J Am Coll Cardiol. 2002;  39 202-209
• 43 Mueller C, Scholer A, Laule-Kilian K. et al . Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.  N Engl J Med. 2004;  350 647-654
• 44 Goetze J P, Christoffersen C, Perko M. et al . Increased cardiac BNP expression associated with myocardial ischemia.  FASEB. 2003;  17 1105-1107
• 45 Wiviott S D, Cannon C P, Morrow D A. et al . Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 substudy.  Circulation. 2004;  109 580-586
• 46 De Lemos J A, Morrow D A, Bentley J H. et al . The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.  N Engl J Med. 2001;  345 1014-1021
• 47 Morrow D A, de Lemos J A, Sabatine M S. et al . Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18.  J Am Coll Cardiol. 2003;  41 1264-1272
• 48 Richards A M, Nicholls M G, Espiner E A. et al . B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction.  Circulation. 2003;  107 2786-2792
• 49 Kucher N, Printzen G, Goldhaber S Z. Prognostic role of brain natriuretic peptide in acute pulmonary embolism.  Circulation. 2003;  107 2545-2547
• 50 Troughton R W, Frampton C M, Yandle T G. et al . Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.  Lancet. 2000;  355 1126-1130
• 51 Tsutamoto T, Wada A, Maeda K. et al . Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure.  J Am Coll Cardiol. 2001;  37 1228-1233
• 52 Richards A M, Doughty R, Nicholls M G. et al . Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction.  Circulation. 1999;  99 786-792
• 53 Latini R, Masson S, Anand I. et al . Effects of Valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).  Circulation. 2002;  106 2454-2458
• 54 Wang T, Larson M G, Levy D. et al . Plasma natriuretic peptide levels and the risk of cardiovascular event and death.  N Engl J Med. 2004;  350 655-663
• 55 Colucci W S, Elkayam U, Horton D P. et al . Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.  N Engl J Med. 2000;  343 246-253
• 56 Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF) . Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.  JAMA. 2002;  287 1531-1540
• 57 Moazami N, Damiano R J, Bailey M S. et al . Nesiritide (BNP) in the management of postoperative cardiac patients.  Ann Thorac Surg. 2003;  75 1974-1976
• 58 De Denus S, Pharand C, Williamson D R. Brain natriuretic peptide in the management of heart failure.  Chest. 2004;  125 652-668